Cargando…
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This s...
Autores principales: | Verspoor, F. G. M., Mastboom, M. J. L., Hannink, G., Maki, R. G., Wagner, A., Bompas, E., Desai, J., Italiano, A., Seddon, B. M., van der Graaf, W. T. A., Blay, J.-Y., Brahmi, M., Eberst, L., Stacchiotti, S., Mir, O., van de Sande, M. A. J., Gelderblom, H., Cassier, P. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786996/ https://www.ncbi.nlm.nih.gov/pubmed/31601938 http://dx.doi.org/10.1038/s41598-019-51211-y |
Ejemplares similares
-
Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases
por: Mastboom, Monique J. L., et al.
Publicado: (2017) -
Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
por: Mastboom, Monique J L, et al.
Publicado: (2017) -
Cryosurgery as Additional Treatment in Tenosynovial Giant Cell Tumors
por: Verspoor, F. G. M., et al.
Publicado: (2016) -
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013) -
Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
por: Mastboom, Monique J L, et al.
Publicado: (2018)